Emfizatamab
- Generic Name
- Emfizatamab
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06857227
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06857214
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
- Conditions
- Non-Hodgkin LymphomaVascular Immunomother T Cell LymphomaNK/T Cell Lymphoma
- Interventions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05627856
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05623982
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Harbin First Hospital, Haerbin, Heilongjing, China
🇨🇳Qingdao Central Hospital, Qingdao, Shandong, China
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
- Conditions
- Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05485753
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Beijing GoBroad Boren Hospital, Beijing, Beijing, China
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05192486
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, Hebei, China
🇨🇳The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT04606433
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.